SG10201701380TA - Biomarkers and methods of treating pd-1 and pd-l1 related conditions - Google Patents
Biomarkers and methods of treating pd-1 and pd-l1 related conditionsInfo
- Publication number
- SG10201701380TA SG10201701380TA SG10201701380TA SG10201701380TA SG10201701380TA SG 10201701380T A SG10201701380T A SG 10201701380TA SG 10201701380T A SG10201701380T A SG 10201701380TA SG 10201701380T A SG10201701380T A SG 10201701380TA SG 10201701380T A SG10201701380T A SG 10201701380TA
- Authority
- SG
- Singapore
- Prior art keywords
- biomarkers
- treating
- methods
- related conditions
- conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0241—Advertisements
- G06Q30/0251—Targeted advertisements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361802296P | 2013-03-15 | 2013-03-15 | |
US201361812678P | 2013-04-16 | 2013-04-16 | |
US201361829236P | 2013-05-30 | 2013-05-30 | |
US201361883186P | 2013-09-26 | 2013-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201701380TA true SG10201701380TA (en) | 2017-04-27 |
Family
ID=50391526
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201701380TA SG10201701380TA (en) | 2013-03-15 | 2014-03-12 | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
SG11201507333XA SG11201507333XA (en) | 2013-03-15 | 2014-03-12 | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201507333XA SG11201507333XA (en) | 2013-03-15 | 2014-03-12 | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
Country Status (18)
Country | Link |
---|---|
US (2) | US11299544B2 (en) |
EP (3) | EP4356960A2 (en) |
JP (2) | JP6483082B2 (en) |
KR (5) | KR20220053691A (en) |
CN (2) | CN105209919B (en) |
AU (4) | AU2014235453A1 (en) |
BR (1) | BR112015023120A2 (en) |
CA (2) | CA3180286A1 (en) |
ES (1) | ES2761260T3 (en) |
HK (1) | HK1212769A1 (en) |
IL (2) | IL241309B (en) |
MX (2) | MX2015011774A (en) |
MY (2) | MY197809A (en) |
NZ (3) | NZ712314A (en) |
PL (1) | PL2972373T3 (en) |
RU (1) | RU2701378C2 (en) |
SG (2) | SG10201701380TA (en) |
WO (1) | WO2014151006A2 (en) |
Families Citing this family (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011050103A1 (en) | 2009-10-21 | 2011-04-28 | The Scripps Research Institute | Method of using non-rare cells to detect rare cells |
CN104655854A (en) | 2008-04-09 | 2015-05-27 | 健泰科生物技术公司 | Novel compositions and methods for the treatment of immune related diseases |
SG10201708690SA (en) | 2008-12-09 | 2017-12-28 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
EP2714937B1 (en) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
BR112015023120A2 (en) | 2013-03-15 | 2017-11-21 | Genentech Inc | method for identifying an individual with a disease or dysfunction, method for predicting the responsiveness of an individual with a disease or dysfunction, method for determining the likelihood that an individual with a disease or dysfunction will exhibit benefit from treatment, method for selecting a therapy, Uses of a pd-11 Axis Binding Antagonist, Assay to Identify an Individual with a Disease, Diagnostic Kit, Method to Evaluate a Treatment Response, and Method to Monitor the Response of a Treated Individual |
KR20230118704A (en) | 2013-07-16 | 2023-08-11 | 제넨테크, 인크. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
EP3084001A4 (en) * | 2013-12-17 | 2017-07-12 | Merck Sharp & Dohme Corp. | Gene signature biomarkers of tumor response to pd-1 antagonists |
AU2014364601A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies |
WO2015094996A2 (en) * | 2013-12-17 | 2015-06-25 | Merck Sharp & Dohme Corp. | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
TWI680138B (en) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
WO2015112955A1 (en) | 2014-01-27 | 2015-07-30 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
EP3108246B1 (en) | 2014-02-21 | 2019-10-09 | Epic Sciences, Inc. | Methods for analyzing rare circulating cells |
EP3166974A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
US20170275347A1 (en) * | 2014-09-05 | 2017-09-28 | Medimmune Limited | Methods for identifying patients responsive to anti-pd-l1 antibody therapy |
CN106999536B (en) | 2014-09-11 | 2020-11-27 | 百时美施贵宝公司 | Macrocyclic inhibitors of PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
US20170242016A1 (en) * | 2014-10-15 | 2017-08-24 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for therapy targeting pd-l1 |
WO2016077709A1 (en) | 2014-11-14 | 2016-05-19 | Liquid Genomics, Inc. | Use of circulating cell-free rna for diagnosis and/or monitoring cancer |
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
US10746726B2 (en) * | 2014-12-02 | 2020-08-18 | The University Of Tokyo | Method for assessing therapeutic effect of anti-cancer agent having anti-CD4 antibody as active ingredient |
EP3230498B1 (en) * | 2014-12-09 | 2023-01-18 | Merck Sharp & Dohme LLC | System and methods for deriving gene signature biomarkers of response to pd-1 antagonists |
US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
JP6737185B2 (en) * | 2015-01-29 | 2020-08-05 | コニカミノルタ株式会社 | Simultaneous detection of blood cells with interacting molecules |
US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
AU2016222928B2 (en) | 2015-02-26 | 2021-05-13 | Merck Patent Gmbh | PD-1 / PD-L1 inhibitors for the treatment of cancer |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
KR20170135860A (en) | 2015-03-13 | 2017-12-08 | 싸이톰스 테라퓨틱스, 인크. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of using them |
US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
PL3273992T3 (en) | 2015-03-23 | 2020-11-16 | Jounce Therapeutics, Inc. | Antibodies to icos |
EP3283882B1 (en) | 2015-04-17 | 2020-12-16 | Merck Sharp & Dohme Corp. | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
IL295002A (en) | 2015-05-12 | 2022-09-01 | Genentech Inc | Therapeutic and diagnostic methods for cancer comprising a pd-l1 binding antagonist |
EP3303619B1 (en) | 2015-05-29 | 2020-06-10 | H. Hoffnabb-La Roche Ag | Pd-l1 promoter methylation in cancer |
KR20180012753A (en) * | 2015-05-29 | 2018-02-06 | 제넨테크, 인크. | Treatment and Diagnosis Methods for Cancer |
KR20180025888A (en) * | 2015-06-08 | 2018-03-09 | 제넨테크, 인크. | Methods for treating cancer using anti-OX40 antibodies and PD-1 axis-binding antagonists |
EP3310810A1 (en) | 2015-06-16 | 2018-04-25 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
RU2729936C2 (en) | 2015-06-16 | 2020-08-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Anticancer agent |
KR20180018538A (en) | 2015-06-17 | 2018-02-21 | 제넨테크, 인크. | Methods for the treatment of locally advanced or metastatic breast cancer using PD-1 axis-binding antagonists and taxanes |
WO2017024465A1 (en) * | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
CA2995502A1 (en) | 2015-09-21 | 2017-03-30 | Merck Sharp & Dohme Corp. | Antibody that binds to human programmed death ligand 2 (pd-l2) and uses thereof |
JP6831112B2 (en) * | 2015-10-15 | 2021-02-17 | 国立大学法人京都大学 | Biomarkers for predicting the efficacy of PD-1 pathway inhibitors |
TW201723190A (en) | 2015-10-22 | 2017-07-01 | 永斯醫療股份有限公司 | Gene signatures for determining ICOS expression |
SI3368683T1 (en) * | 2015-10-27 | 2020-07-31 | Pharmassist Ltd | Method for the quantification of pd-l1 |
CR20180306A (en) | 2015-11-02 | 2018-10-16 | Five Prime Therapeutics Inc | CD80 EXTRACELLULAR DOMAIN POLIPEPTIDES AND ITS USE IN CANCER TREATMENT |
CN107614529B (en) | 2015-11-17 | 2019-11-12 | 苏州盛迪亚生物医药有限公司 | PD-L1 antibody, its antigen-binding fragment and its medical usage |
US20180364240A1 (en) * | 2015-12-10 | 2018-12-20 | Medimmune, Llc | Methods for treatment and selection of patients responsive to immune mediated cancer therapy |
CN106939047B (en) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | PD-L1 antibody and preparation method thereof |
EP3862365A1 (en) | 2016-01-08 | 2021-08-11 | F. Hoffmann-La Roche AG | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
CN105717298A (en) * | 2016-01-29 | 2016-06-29 | 浙江数问生物技术有限公司 | PD-L1 immunohistochemical kit |
WO2017139755A1 (en) * | 2016-02-12 | 2017-08-17 | Rekoske Brian T | Cancer therapy |
WO2017151517A1 (en) | 2016-02-29 | 2017-09-08 | Foundation Medicine, Inc. | Methods of treating cancer |
AU2017225854B2 (en) * | 2016-02-29 | 2020-11-19 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
EP3309177B1 (en) * | 2016-03-04 | 2020-05-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Pdl-1 antibody, pharmaceutical composition thereof, and uses thereof |
WO2017161976A1 (en) * | 2016-03-23 | 2017-09-28 | Mabspace Biosciences (Suzhou) Co., Ltd | Novel anti-pd-l1 antibodies |
US10613092B2 (en) | 2016-04-01 | 2020-04-07 | Agilent Technologies, Inc. | Scoring methods for anti-PD therapy eligibility and compositions for performing same |
US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
MX2018012492A (en) * | 2016-04-15 | 2019-06-06 | Genentech Inc | Methods for monitoring and treating cancer. |
TWI822521B (en) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | Methods of treating skin cancer by administering a pd-1 inhibitor |
DE102016005947B3 (en) * | 2016-05-16 | 2017-06-08 | Dimo Dietrich | A method for estimating the prognosis and predicting the response to immunotherapy of patients with malignant diseases |
KR20190007026A (en) * | 2016-05-17 | 2019-01-21 | 제넨테크, 인크. | Substrate Gene Properties for Diagnosis and Use in Immunotherapy |
EP3827849A1 (en) | 2016-05-19 | 2021-06-02 | Bristol-Myers Squibb Company | Pet-imaging immunomodulators |
WO2017213117A1 (en) * | 2016-06-10 | 2017-12-14 | 公益財団法人がん研究会 | Multiple staining method and staining kit |
US10961504B2 (en) | 2016-06-27 | 2021-03-30 | Yeda Research And Development Co. Ltd. | Veto cells generated from memory T cells |
CN109843931A (en) * | 2016-08-11 | 2019-06-04 | 昆士兰医学研究所理事会 | Immunomodulatory compounds |
CN106198984B (en) * | 2016-08-22 | 2019-07-05 | 上海立闻生物科技有限公司 | The detection method of Peripheral Blood of Patients with Non-small Cell Lung circulating tumor cell PDL1 gene |
EP3515456A4 (en) * | 2016-09-20 | 2020-06-17 | Medimmune, LLC | Compositions and methods for characterizing solid tumors responsiveness to anti-pd-l1 antibody monotherapy |
KR20190072528A (en) | 2016-10-06 | 2019-06-25 | 제넨테크, 인크. | Treatment and Diagnosis Methods for Cancer |
CN109843324A (en) | 2016-10-06 | 2019-06-04 | 辉瑞公司 | AVELUMAB therapeutic regimen for treating cancer |
MD3535298T2 (en) | 2016-11-02 | 2022-01-31 | Jounce Therapeutics Inc | Antibodies to pd-1 and uses thereof |
KR102526034B1 (en) | 2016-11-07 | 2023-04-25 | 브리스톨-마이어스 스큅 컴퍼니 | immunomodulator |
KR20190095921A (en) * | 2016-12-12 | 2019-08-16 | 제넨테크, 인크. | How to Treat Cancer Using Anti-PD-L1 Antibody and Antiandrogen |
WO2018123999A1 (en) * | 2016-12-28 | 2018-07-05 | 学校法人近畿大学 | Method for selecting individuals to be administered immune checkpoint inhibitor |
AU2018211064A1 (en) * | 2017-01-18 | 2019-09-05 | Genentech, Inc. | Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof |
WO2018145023A1 (en) * | 2017-02-06 | 2018-08-09 | Novartis Ag | Method of predicting response to immunotherapy |
CA3052670A1 (en) | 2017-03-01 | 2018-09-07 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
EP3601355A1 (en) | 2017-03-31 | 2020-02-05 | Bristol-Myers Squibb Company | Methods of treating tumor |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
CN110621787A (en) * | 2017-04-14 | 2019-12-27 | 豪夫迈·罗氏有限公司 | Methods for diagnosis and treatment of cancer |
CN110546509A (en) | 2017-04-28 | 2019-12-06 | 戊瑞治疗有限公司 | Methods of treatment with CD80 extracellular domain polypeptides |
US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
CA3066054A1 (en) * | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer therapy and kit therefor |
US11066445B2 (en) | 2017-06-23 | 2021-07-20 | Bristol-Myers Squibb Company | Immunomodulators acting as antagonists of PD-1 |
US10636512B2 (en) | 2017-07-14 | 2020-04-28 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
TWI823859B (en) | 2017-07-21 | 2023-12-01 | 美商建南德克公司 | Therapeutic and diagnostic methods for cancer |
KR20200058506A (en) | 2017-10-03 | 2020-05-27 | 브리스톨-마이어스 스큅 컴퍼니 | Immunomodulators |
KR101982001B1 (en) * | 2017-10-13 | 2019-05-27 | 한국과학기술원 | Method for selecting of anti-pd-1 or anti-pd-l1 antibodies using alloimmunity or xenoimmunity |
EP3694884A1 (en) | 2017-10-15 | 2020-08-19 | Bristol-Myers Squibb Company | Methods of treating tumor |
US20210341483A1 (en) * | 2017-11-30 | 2021-11-04 | Singapore Health Services Pte. Ltd. | System and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient |
CN108179134B (en) * | 2017-12-27 | 2020-11-24 | 武汉大学 | EpCAM/PSMA-based double-antibody functionalized microfluidic chip and preparation method and application thereof |
WO2019137397A1 (en) * | 2018-01-10 | 2019-07-18 | 江苏恒瑞医药股份有限公司 | Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
CN112204401A (en) * | 2018-01-18 | 2021-01-08 | 优创匹克制药公司 | Method for predicting cancer drug responsiveness |
KR102089241B1 (en) * | 2018-02-05 | 2020-03-16 | 한국과학기술원 | A method for prediction of the immunotherapy effects to cancer patients |
JPWO2019159825A1 (en) * | 2018-02-14 | 2021-02-04 | 国立大学法人東海国立大学機構 | Biomarker predicting the effect of anti-PD-1 antibody / anti-PD-L1 antibody therapy |
TW202000702A (en) * | 2018-02-26 | 2020-01-01 | 美商建南德克公司 | Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies |
WO2019169145A1 (en) * | 2018-02-28 | 2019-09-06 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
US20190302124A1 (en) * | 2018-03-27 | 2019-10-03 | Laboratory Corporation Of America Holdings | Compositions and Methods for Identifying Subjects Who May Benefit From Treatment With Therapeutic Agents |
EP3793557A1 (en) * | 2018-05-14 | 2021-03-24 | Merck Sharp & Dohme Corp. | Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist |
KR102091637B1 (en) * | 2018-07-10 | 2020-03-20 | 연세대학교 산학협력단 | Methods for poviding information about responses to cancer immunotherapy and kits using the same |
CN109116032B (en) * | 2018-08-01 | 2021-09-03 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | Kit for detecting PD-L1 antibody immunotherapy and prognosis of prostate cancer patient |
KR102084196B1 (en) * | 2018-08-29 | 2020-03-03 | 연세대학교 산학협력단 | Methods for providing information about responses to cancer immunotherapy and kits using the same |
JP2022501332A (en) | 2018-09-19 | 2022-01-06 | ジェネンテック, インコーポレイテッド | How to treat and diagnose bladder cancer |
WO2020081767A1 (en) | 2018-10-18 | 2020-04-23 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
KR102195135B1 (en) * | 2018-12-07 | 2020-12-24 | 한국과학기술원 | A screening method of immunomodulators |
AU2019403339A1 (en) * | 2018-12-19 | 2021-07-08 | Strata Oncology, Inc. | Methods of detecting and treating subjects with checkpoint inhibitor-responsive cancer |
KR102159538B1 (en) * | 2019-01-11 | 2020-09-24 | 충남대학교 산학협력단 | IL-6 marker for predicting treatment response of a patient with lung cancer to cancer immunotherapy and uses thereof |
CN109596831B (en) * | 2019-01-14 | 2020-05-29 | 臻悦生物科技江苏有限公司 | Multiple immunohistochemical analysis kit for lung cancer and use method and application thereof |
CN113166815A (en) * | 2019-02-22 | 2021-07-23 | 深圳华大生命科学研究院 | Application of intestinal metagenome in screening curative effect of PD-1 antibody blocking agent |
WO2020172592A1 (en) * | 2019-02-22 | 2020-08-27 | Mitra Rxdx, Inc. | A method to predict a patient's response to an anti-cancer drug from a ratio of expression levels of two sets of genes |
EP3951947A4 (en) | 2019-03-27 | 2022-12-28 | Sumitomo Metal Mining Co., Ltd. | Positive-electrode active material for lithium-ion secondary cell, method for manufacturing positive-electrode active material, and lithium-ion secondary cell |
CN109884303B (en) * | 2019-03-29 | 2020-05-29 | 臻悦生物科技江苏有限公司 | Multiple immunohistochemical analysis kit for liver cancer and use method and application thereof |
JP2020187127A (en) * | 2019-05-15 | 2020-11-19 | 上準微流體股▲ふん▼有限公司MiCareo Taiwan Co., Ltd. | Method for predicting immunotherapy response of subject having cancer |
CN110687281B (en) * | 2019-08-26 | 2023-05-23 | 中国医学科学院肿瘤医院 | Application of PD-L1 autoantibody in tumor prognosis evaluation |
US20210088523A1 (en) * | 2019-09-23 | 2021-03-25 | Sri International | Methods for detecting circulating tumor cells in non-small cell lung cancer |
US20210116454A1 (en) * | 2019-10-21 | 2021-04-22 | Celgene Corporation | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
CN110927389B (en) * | 2019-11-29 | 2021-07-16 | 中国科学院苏州生物医学工程技术研究所 | Cancer biomarker and application |
KR102371903B1 (en) * | 2019-12-24 | 2022-03-08 | 주식회사 테라젠바이오 | Methods for poviding information about responses to cancer immunotherapy and devices using the same |
WO2021202959A1 (en) * | 2020-04-03 | 2021-10-07 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
CN111521796A (en) * | 2020-04-21 | 2020-08-11 | 山东第一医科大学(山东省医学科学院) | Immunofluorescence kit and detection method for detecting expression of peripheral blood circulating tumor cells PD-L1 of renal cancer patient |
CN111521792A (en) * | 2020-04-21 | 2020-08-11 | 山东第一医科大学(山东省医学科学院) | Immunofluorescence kit and method for detecting non-small cell lung cancer patient peripheral blood circulating tumor cell PD-L1 gene mutation |
WO2021222167A1 (en) | 2020-04-28 | 2021-11-04 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
WO2021228888A1 (en) | 2020-05-12 | 2021-11-18 | Asylia Diagnostics | Biomarkers for hyperprogressive disease and therapy response after immunotherapy |
CN111863126B (en) * | 2020-05-28 | 2024-03-26 | 上海市生物医药技术研究院 | Method for constructing colorectal tumor state evaluation model and application |
WO2021247540A1 (en) * | 2020-06-01 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Methods for modulating mhc-i expression and immunotherapy uses thereof |
WO2022135402A1 (en) * | 2020-12-24 | 2022-06-30 | 信达生物制药(苏州)有限公司 | Use of pd-l1 and/or mhc-2 biomarker in prediction of therapeutic efficacy in lung cancer patients |
CN113109565B (en) * | 2021-04-12 | 2024-02-02 | 中国人民解放军空军军医大学 | Detection box for evaluating sensitivity of patient to PD-1 monoclonal antibody product and application thereof |
RU2766739C1 (en) * | 2021-04-12 | 2022-03-15 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) | Method for prediction of clinical effectiveness in melanoma |
CN113358872B (en) * | 2021-06-03 | 2022-10-21 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | Marker group and system for evaluating curative effect of tumor immunotherapy |
AU2022315526A1 (en) | 2021-07-22 | 2024-02-29 | Asylia Diagnostics Bv | Biomarkers for therapy response after immunotherapy |
CA3227993A1 (en) | 2021-08-11 | 2023-02-16 | OncoHost Ltd. | Predicting patient response |
CN114022472B (en) * | 2021-11-17 | 2022-05-20 | 深圳裕策生物科技有限公司 | Tumor infiltrating lymphocyte analysis method, device and storage medium |
WO2024011295A1 (en) * | 2022-07-14 | 2024-01-18 | University Of South Australia | Methods and products for determining responsiveness to anti-pd1 immune checkpoint inhibitor immunotherapy |
CN117701719A (en) * | 2024-02-04 | 2024-03-15 | 北京肿瘤医院(北京大学肿瘤医院) | Tumor targeting CLDN18.2 therapeutic drug-resistant marker and application thereof |
CN117741148A (en) * | 2024-02-19 | 2024-03-22 | 苏州颐坤生物科技有限公司 | Marker combination for predicting curative effect of immunotherapy and model construction method and application |
Family Cites Families (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
EP0138854B1 (en) | 1983-03-08 | 1992-11-04 | Chiron Mimotopes Pty. Ltd. | Antigenically active amino acid sequences |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
AU4434585A (en) | 1985-03-30 | 1986-10-23 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5266684A (en) | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
KR0184860B1 (en) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | Single domain ligands receptors comprising said ligands methods for their production and use of said ligands |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5498538A (en) | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
CA2090860C (en) | 1990-11-21 | 2003-09-16 | Richard A. Houghten | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
ATE164395T1 (en) | 1990-12-03 | 1998-04-15 | Genentech Inc | METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DE69333807T2 (en) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | MARKERS FOR CANCER AND BIOSYNTHETIC BINDEPROTEIN THEREFOR |
WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5922855A (en) | 1993-12-17 | 1999-07-13 | Oregon Health Sciences University | Mammalian DNA mismatch repair genes MLH1 and PMS1 |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
EP0760012A4 (en) | 1994-06-10 | 1997-07-02 | Symbiotech Inc | Method of detecting compounds utilizing genetically modified lambdoid bacteriophage |
US5627024A (en) | 1994-08-05 | 1997-05-06 | The Scripps Research Institute | Lambdoid bacteriophage vectors for expression and display of foreign proteins |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
DE69628026T2 (en) | 1995-09-07 | 2004-04-08 | Novozymes A/S | DETECTION OF THE ACTIVITY OF ENZYMES FOR DETERGENTS BY PHAGE. |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
JP2000510443A (en) | 1996-03-20 | 2000-08-15 | ダイアックス コープ. | Purification of tissue plasminogen activator (tPA) |
JP2000512981A (en) | 1996-06-06 | 2000-10-03 | ラ ホヤ ファーマシューティカル カンパニー | aPL immunoreactive peptide, conjugate thereof and method of treatment for aPL antibody-mediated pathology |
CA2257873A1 (en) | 1996-06-10 | 1997-12-18 | The Scripps Research Institute | Use of substrate subtraction libraries to distinguish enzyme specificities |
US5766905A (en) | 1996-06-14 | 1998-06-16 | Associated Universities Inc. | Cytoplasmic bacteriophage display system |
EP0929361A4 (en) | 1996-10-04 | 2000-07-19 | Whatman Inc | Device and method for simultaneous multiple chemical syntheses |
JP2001512560A (en) | 1996-10-08 | 2001-08-21 | ユー―ビスイス ベスローテン フェンノートシャップ | Methods and means for the selection of peptides and proteins with specific affinity for a target |
AU745101B2 (en) | 1996-11-06 | 2002-03-14 | Genentech Inc. | Constrained helical peptides and methods of making same |
IL119586A (en) | 1996-11-07 | 2001-09-13 | Univ Ramot | Discontinuous library of a single biological unit and a method for its preparation |
IL119587A (en) | 1996-11-07 | 2000-12-06 | Univ Ramot | Method of preparing and for obtaining bimolecular interactions |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
DE69830315T2 (en) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | GALACTOSYLATED GLYCOPROTEIN CONTAINING COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF |
CA2307330A1 (en) | 1997-10-21 | 1999-04-29 | The University Court Of The University Of Glasgow | Jmy, a co-activator for p300/cbp, nucleic acid encoding jmy and uses thereof |
EP1028751B1 (en) | 1997-10-31 | 2008-12-31 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
DK1034298T3 (en) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanization of murine antibody |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
ES2340112T3 (en) | 1998-04-20 | 2010-05-28 | Glycart Biotechnology Ag | ANTIBODY GLICOSILATION ENGINEERING FOR THE IMPROVEMENT OF DEPENDENT CELLULAR CYTOTOXICITY OF ANTIBODIES. |
US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
WO2000039585A1 (en) | 1998-12-28 | 2000-07-06 | Sunesis Pharmaceuticals, Inc. | Identifying small organic molecule ligands for binding |
WO2000042072A2 (en) | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
MXPA02001878A (en) | 1999-08-23 | 2003-08-20 | Dana Farber Cancer Inst Inc | Novel b74 molecules and uses therefor. |
JP4668498B2 (en) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | Method for producing polypeptide |
US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
WO2001044463A1 (en) | 1999-12-15 | 2001-06-21 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
DK1242438T3 (en) | 1999-12-29 | 2007-02-12 | Immunogen Inc | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
LT2857516T (en) | 2000-04-11 | 2017-09-11 | Genentech, Inc. | Multivalent antibodies and uses therefor |
PL218428B1 (en) | 2000-10-06 | 2014-12-31 | Kyowa Hakko Kogyo Kk | Cells producing antibody compositions |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
ES2362419T3 (en) | 2002-04-09 | 2011-07-05 | Kyowa Hakko Kirin Co., Ltd. | CELLS WITH DEPRESSION OR DELETION OF THE ACTIVITY OF THE PROTEIN THAT PARTICIPATES IN THE TRANSPORT OF GDP-FUCOSA. |
US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
WO2003084569A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Drug containing antibody composition |
AU2003239966B9 (en) | 2002-06-03 | 2010-08-26 | Genentech, Inc. | Synthetic antibody phage libraries |
DE60200248T2 (en) * | 2002-08-01 | 2005-01-27 | Mtm Laboratories Ag | Procedure for solution-based diagnosis |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
AR042485A1 (en) | 2002-12-16 | 2005-06-22 | Genentech Inc | HUMANIZED ANTIBODY THAT JOINS THE HUMAN CD20 |
CA2510003A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
EA036531B1 (en) | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Type ii anti-cd20 humanized antibody (variants), pharmaceutical composition comprising these antibody variants, and use thereof |
ZA200603619B (en) | 2003-11-06 | 2008-10-29 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
WO2005053742A1 (en) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicine containing antibody composition |
ZA200608130B (en) | 2004-03-31 | 2008-12-31 | Genentech Inc | Humanized anti-TGF-beta antibodies |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
CA2561533C (en) | 2004-04-13 | 2015-06-16 | Yvo Graus | Anti-p-selectin antibodies |
AU2012211347B9 (en) * | 2004-07-20 | 2015-06-18 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
CN101084438B (en) * | 2004-10-06 | 2013-12-25 | 梅约医学教育与研究基金会 | B7-H1 and methods of diagnosis, prognosis, and treatment of cancer |
HUE039237T2 (en) | 2004-10-06 | 2018-12-28 | Mayo Found Medical Education & Res | B7-h1 and pd-1 in treatment of renal cell carcinoma |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
EP3130350A1 (en) * | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
AU2006265108C1 (en) * | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
WO2007047955A2 (en) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
US8679490B2 (en) | 2005-11-07 | 2014-03-25 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
WO2007082154A2 (en) | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
WO2007082144A2 (en) * | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and survivin in cancer |
EP1997887B1 (en) * | 2006-03-03 | 2013-09-04 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of cell surface functional molecule |
EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
CN101104640A (en) | 2006-07-10 | 2008-01-16 | 苏州大学 | Preparation for anti human PD-L1 monoclonal antibody and application thereof |
US7895540B2 (en) | 2006-08-02 | 2011-02-22 | Georgia Tech Research Corporation | Multilayer finite difference methods for electrical modeling of packages and printed circuit boards |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
US20090155180A1 (en) * | 2007-02-28 | 2009-06-18 | Mary Lynn Jump | Methods and targets for identifying compounds for regulating rhinovirus infection |
CN100592373C (en) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | Liquid crystal panel drive device and its drive method |
ES2774337T3 (en) | 2008-01-07 | 2020-07-20 | Amgen Inc | Method for manufacturing heterodimeric Fc molecules of antibodies using electrostatic conduction effects |
EP3530672B1 (en) * | 2008-09-26 | 2024-05-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
WO2010056735A1 (en) * | 2008-11-11 | 2010-05-20 | The Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity |
SG10201708690SA (en) | 2008-12-09 | 2017-12-28 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
ES2629337T3 (en) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Antibodies against PD-1 and antibodies against PD-L1 and uses thereof |
CN102428179A (en) * | 2009-03-06 | 2012-04-25 | 国立大学法人三重大学 | Method for enhancing function of T cell |
EP3375791A1 (en) * | 2009-09-30 | 2018-09-19 | Memorial Sloan Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
EP2588443A2 (en) | 2010-07-02 | 2013-05-08 | Ventana Medical Systems, Inc. | Hapten conjugates for target detection |
WO2012006589A2 (en) * | 2010-07-08 | 2012-01-12 | Infinity Pharmaceuticals, Inc. | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling |
DK2612151T3 (en) * | 2010-08-31 | 2017-10-02 | Genentech Inc | BIOMARKETS AND METHODS OF TREATMENT |
KR20130115250A (en) * | 2010-09-15 | 2013-10-21 | 알막 다이아그노스틱스 리미티드 | Molecular diagnostic test for cancer |
HUE037651T2 (en) * | 2011-04-20 | 2018-09-28 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
CN102250911A (en) * | 2011-05-31 | 2011-11-23 | 苏州大学 | Soluble B7-H1 quantitative detection kit |
PE20190262A1 (en) * | 2011-08-01 | 2019-02-25 | Genentech Inc | METHODS FOR TREATING CANCER BY USE OF PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS |
SG11201402603WA (en) | 2011-11-28 | 2014-06-27 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
US9846162B2 (en) | 2012-05-14 | 2017-12-19 | Yale University | Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer |
CN113967253A (en) * | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | Immunotherapy by disrupting PD-1/PD-L1 signaling |
WO2013173233A1 (en) | 2012-05-17 | 2013-11-21 | Baker Hughes Incorporated | Dendritic surfactants and extended surfactants for drilling fluid formulations |
CN111499755A (en) | 2012-08-03 | 2020-08-07 | 丹娜法伯癌症研究院 | anti-PD-L1 and PD-L2 double-binding antibody single reagents and methods of use thereof |
SG11201500903XA (en) | 2012-08-07 | 2015-03-30 | Genentech Inc | Combination therapy for the treatment of glioblastoma |
MX363188B (en) | 2012-11-30 | 2019-03-13 | Hoffmann La Roche | Identification of patients in need of pd-l1 inhibitor cotherapy. |
AR093984A1 (en) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN |
WO2014165082A2 (en) | 2013-03-13 | 2014-10-09 | Medimmune, Llc | Antibodies and methods of detection |
BR112015023120A2 (en) | 2013-03-15 | 2017-11-21 | Genentech Inc | method for identifying an individual with a disease or dysfunction, method for predicting the responsiveness of an individual with a disease or dysfunction, method for determining the likelihood that an individual with a disease or dysfunction will exhibit benefit from treatment, method for selecting a therapy, Uses of a pd-11 Axis Binding Antagonist, Assay to Identify an Individual with a Disease, Diagnostic Kit, Method to Evaluate a Treatment Response, and Method to Monitor the Response of a Treated Individual |
US20150071910A1 (en) | 2013-03-15 | 2015-03-12 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
WO2014165422A1 (en) | 2013-04-02 | 2014-10-09 | Merck Sharp & Dohme Corp. | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
AU2014293155B2 (en) | 2013-07-24 | 2020-01-16 | Dana-Farber Cancer Institute, Inc. | Anti-galectin-1 (Gal1) monoclonal antibodies and fragments thereof for neutralizing Gal1 |
GB201316027D0 (en) | 2013-09-09 | 2013-10-23 | Almac Diagnostics Ltd | Molecular diagnostic test for oesophageal cancer |
GB201316024D0 (en) | 2013-09-09 | 2013-10-23 | Almac Diagnostics Ltd | Molecular diagnostic test for lung cancer |
WO2015038538A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune, Llc | Compositions and methods for treating sepsis |
DK3043816T3 (en) | 2013-09-11 | 2019-10-14 | Medimmune Ltd | ANTI-B7-H1 ANTIBODIES FOR TREATMENT OF TUMORS |
US10202454B2 (en) | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
EP3079772B1 (en) | 2013-12-10 | 2020-02-05 | Merck Sharp & Dohme Corp. | Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue |
WO2015124703A1 (en) | 2014-02-24 | 2015-08-27 | Ventana Medical Systems, Inc. | Quinone methide analog signal amplification |
US20150322184A1 (en) | 2014-05-07 | 2015-11-12 | Chevron Phillips Chemical Company Lp | High Performance Moisture Barrier Films at Lower Densities |
EP3194554A4 (en) | 2014-05-12 | 2018-04-25 | The Procter and Gamble Company | Anti-microbial cleaning composition |
EP3149042B1 (en) | 2014-05-29 | 2019-08-28 | Spring Bioscience Corporation | Pd-l1 antibodies and uses thereof |
CA2947687C (en) | 2014-05-30 | 2021-07-06 | Ventana Medical Systems, Inc. | Multiplex assay for improved scoring of tumor tissues stained for pd-l1 |
EP3166974A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
-
2014
- 2014-03-12 BR BR112015023120A patent/BR112015023120A2/en active Search and Examination
- 2014-03-12 EP EP23217779.0A patent/EP4356960A2/en active Pending
- 2014-03-12 KR KR1020227012872A patent/KR20220053691A/en not_active Application Discontinuation
- 2014-03-12 MY MYPI2018000698A patent/MY197809A/en unknown
- 2014-03-12 WO PCT/US2014/024746 patent/WO2014151006A2/en active Application Filing
- 2014-03-12 CN CN201480027406.7A patent/CN105209919B/en active Active
- 2014-03-12 PL PL14714119T patent/PL2972373T3/en unknown
- 2014-03-12 CA CA3180286A patent/CA3180286A1/en active Pending
- 2014-03-12 KR KR1020157029278A patent/KR20150131269A/en not_active Application Discontinuation
- 2014-03-12 MX MX2015011774A patent/MX2015011774A/en active IP Right Grant
- 2014-03-12 ES ES14714119T patent/ES2761260T3/en active Active
- 2014-03-12 NZ NZ712314A patent/NZ712314A/en unknown
- 2014-03-12 AU AU2014235453A patent/AU2014235453A1/en not_active Abandoned
- 2014-03-12 CA CA2905798A patent/CA2905798C/en active Active
- 2014-03-12 RU RU2015139224A patent/RU2701378C2/en active
- 2014-03-12 MY MYPI2015002278A patent/MY176706A/en unknown
- 2014-03-12 EP EP14714119.6A patent/EP2972373B1/en active Active
- 2014-03-12 EP EP19191154.4A patent/EP3633377A1/en active Pending
- 2014-03-12 JP JP2016501626A patent/JP6483082B2/en active Active
- 2014-03-12 SG SG10201701380TA patent/SG10201701380TA/en unknown
- 2014-03-12 KR KR1020237015323A patent/KR20230070054A/en not_active Application Discontinuation
- 2014-03-12 NZ NZ751260A patent/NZ751260A/en unknown
- 2014-03-12 KR KR1020207026646A patent/KR102389677B1/en active IP Right Grant
- 2014-03-12 CN CN201910113951.2A patent/CN110079599A/en active Pending
- 2014-03-12 NZ NZ751264A patent/NZ751264A/en unknown
- 2014-03-12 KR KR1020187026186A patent/KR102158924B1/en active IP Right Grant
- 2014-03-12 SG SG11201507333XA patent/SG11201507333XA/en unknown
-
2015
- 2015-09-07 MX MX2020008976A patent/MX2020008976A/en unknown
- 2015-09-08 IL IL241309A patent/IL241309B/en active IP Right Grant
- 2015-09-10 US US14/850,462 patent/US11299544B2/en active Active
-
2016
- 2016-01-20 HK HK16100590.6A patent/HK1212769A1/en unknown
-
2017
- 2017-09-07 AU AU2017225061A patent/AU2017225061B2/en active Active
-
2018
- 2018-11-19 JP JP2018216412A patent/JP6845840B2/en active Active
-
2019
- 2019-11-26 IL IL270943A patent/IL270943A/en unknown
- 2019-11-26 AU AU2019271922A patent/AU2019271922C1/en active Active
-
2022
- 2022-03-04 US US17/686,628 patent/US20220363764A1/en active Pending
- 2022-05-30 AU AU2022203671A patent/AU2022203671A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL270943A (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions | |
IL283429A (en) | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors | |
HK1218506A1 (en) | Methods of treating melanoma | |
HK1219975A1 (en) | Cell lines for virus production and methods of use | |
HK1217908A1 (en) | Methods of treating cholangiocarcinoma | |
EP2970317A4 (en) | Pyrimido-diazepinone compounds and methods of treating disorders | |
HK1216546A1 (en) | Method of assessing risk of pml pml | |
GB2513304B (en) | Peripheral apparatus and method of construction | |
SG11201602585XA (en) | Methods of detection and removal of rhabdoviruses from cell lines | |
ZA201600927B (en) | Structural assembly and method of assembly thereof | |
EP3063310A4 (en) | Method of treating metal surfaces | |
HK1223844A1 (en) | Method for the management of cancer and treatment of cancer comorbidities | |
HK1220453A1 (en) | Methods of treating dyskinesia and related disorders | |
HK1212999A1 (en) | Methods for treating and or limiting development of diabetes | |
HK1222323A1 (en) | Compositions and methods for treating conditions that affect epidermis | |
HK1200093A1 (en) | Methods of treating melanoma with pak1 inhibitors pak1 | |
GB201321104D0 (en) | Method and plant for treatment of dispersion | |
GB201910300D0 (en) | Method of and apparatuses for indentifying geological characteristics | |
AU2013904630A0 (en) | Method of treating melanoma |